Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis

By  

Fundamental & Clinical Pharmacology, Vol. 30, Iss. 5, 2016-10 ,pp. : 459-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetic/Pharmacodynamic Profile of Voriconazole

By Theuretzbacher Ursula  

Clinical Pharmacokinetics, Vol. 45, Iss. 7, 2006-01 ,pp. : 649-663

Adis International

Access to resources Recommend Favorite

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

By Miura M.   Tada H.   Yasui-Furukori N.   Uno T.   Sugawara K.   Tateishi T.   Suzuki T.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 623-628

Springer Publishing Company

Access to resources Recommend Favorite

A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy

By Verstuyft Céline   Delavenne Xavier  

Clinical Pharmacokinetics, Vol. 51, Iss. 1, 2012-01 ,pp. : 41-53

Adis International

Access to resources Recommend Favorite

Hydroxylation of R (+)- and S (−)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes

By Shiohira Hideo  

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2310-2316

Springer Publishing Company

Access to resources Recommend Favorite